The annual meeting of the EADV 2022 congress was again a live and lively event, full of discovery and innovation. After the many web-conferences, the live meeting was well appreciated by thousands of European dermatologists. It was worthwhile to meet live with colleagues and to have continuing medical education with the human touch instead of the click of the mouse.
In psoriasis, systemics (the biologic bimekizumab and the small molecule deucravacitinib) and the new topicals (PDE-4 inhibitors and tapinarof) were the innovations. In atopic dermatitis, the biologics (IL-13 inhibitors and IL-22 inhibitors) and a wide range of Janus kinase inhibitors provide unprecedented introduction of new treatments.
Both in psoriasis and atopic dermatitis, there is a need to develop strategies which we collectively designated as personalised medicine. This implies the development of biomarkers.
At this EADV, the biologics and non-biologic systemics are also developed for different fields in dermatology, where innovations were more seldom: hydradenitis chronica suppurativa, vitiligo, and alopecia areata.
Also sun protection, skin cancer, and pruritus were in the spotlight as common concerns.
The present report aims to give an overview of innovations as presented at EADV 2022.
Best regards,
Peter CM van de Kerkhof
Senior professor of Dermatology, Radboud University Nijmegen Medical Centre, the Netherlands
Biography
Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the
ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.
Conflict of Interest Statement: Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Sandoz, Mitsubishi Tanabe, Bristol Meyer Squibb, UCB, Dermavant. Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.Posted on
Previous Article
« High rate of non- or partial responders jeopardises therapeutic success in HS Next Article
ECTRIMS 2022 Highlights Podcast »
« High rate of non- or partial responders jeopardises therapeutic success in HS Next Article
ECTRIMS 2022 Highlights Podcast »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding âhealth benefitâ of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may Îș-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Markedly lower skin cancer risk in vitiligo patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com